ADAMTS13 activity below 10% strongly supports TTP when low platelets and red-cell destruction occur together, but an isolated result does not prove an acute episode. Suspected TTP needs emergency assessment and treatment decisions without waiting for the laboratory result.
- Severe deficiency means ADAMTS13 activity below 10%; this strongly supports TTP in a compatible clinical presentation.
- Akutt vurdering takes priority when thrombocytopenia and microangiopathic hemolytic anemia suggest TTP, even before ADAMTS13 results return.
- Activity measures enzyme function; 5% activity does not mean a 5% probability of having TTP.
- Inhibitor testing detects functional interference with ADAMTS13, while antibody testing can detect binding antibodies that do not inhibit the laboratory reaction.
- Pretreatment sampling is preferred because plasma infusion or exchange can raise activity and reduce detectable antibody or inhibitor levels.
- Borderline activity around 10–20% requires specialist interpretation; it cannot safely settle a strongly suspicious presentation by itself.
- Clinical remission can coexist with activity below 10%; a low follow-up result signals relapse risk rather than automatically proving an acute relapse.
- AI-tolkning can help explain reports but must never delay emergency care or replace a hematologist's treatment decisions.
Does low ADAMTS13 activity automatically mean TTP?
Low ADAMTS13 activity does not automatically mean an acute TTP episode. Activity below 10% strongly supports thrombotic thrombocytopenic purpura when the patient also has thrombocytopenia and microangiopathic hemolytic anemia; suspected TTP requires emergency assessment without waiting for confirmation.
The 2020 ISTH diagnostic guideline identifies ADAMTS13 activity below 10% as the hallmark laboratory finding of TTP, interpreted alongside the presentation and sample timing (Zheng et al., 2020). A person with activity of 4%, falling platelets, and fragmented red cells needs a very different response from someone with the same activity during established remission.
Consider an illustrative patient with platelets of 18 × 10⁹/L, hemoglobin of 8.7 g/dL, and new confusion: that combination warrants immediate hospital assessment, not a routine repeat appointment. The schistocyte interpretation guide explains why fragmented cells add urgency, although their absence on an early slide does not safely exclude TTP.
Kantesti er en AI-blodprøveanalysator that can help explain why activity below 10% matters alongside platelet and hemolysis results, but it cannot determine whether you are safe at home. My approach as Thomas Klein, MD, is to separate two questions immediately: does this suggest severe enzyme deficiency, and is there evidence of an emergency happening now?
What does ADAMTS13 do, and why does 10% matter?
ADAMTS13 cuts unusually large von Willebrand factor multimers into smaller forms, limiting inappropriate platelet attachment in small vessels. Activity below 10% represents severe loss of that function; it is not a percentage estimate of disease probability or a measure of platelet number.
Without enough working enzyme, large von Willebrand factor multimers can recruit platelets into microvascular aggregates, consuming circulating platelets and injuring red cells passing through narrowed channels. That explains the apparently contradictory combination of clot-related organ injury and a low platelet count; an activity of 3% describes enzyme function, not the amount of clotting throughout the body.
Det 10% threshold comes from clinical evidence distinguishing severe ADAMTS13 deficiency from many other thrombotic microangiopathies, not from a sharp biological switch between 9% and 11%. Near that boundary, assay variation, treatment exposure, and the clinical pattern deserve attention; a hematologist may request confirmation using another method when the result and presentation disagree.
Many laboratories report adult reference intervals roughly around 50–150%, but the actual interval is assay-specific and may differ substantially. Do not confuse TTP with von Willebrand disease: the von Willebrand disease testing guide describes a predominantly bleeding disorder involving the protein that ADAMTS13 normally processes, rather than the same enzyme deficiency.
Which accompanying results make TTP more likely?
Thrombocytopenia plus microangiopathic hemolytic anemia is the central laboratory pattern that raises suspicion for TTP. Supporting findings include schistocytes, increased LDH and indirect bilirubin, reduced haptoglobin, and organ injury; clinicians do not require the classic five-feature presentation before acting.
Platelets are often markedly reduced, sometimes below 30 × 10⁹/L, but a higher count does not exclude evolving TTP. Hemoglobin can also lag behind the process early on, so the direction of change matters; a fall from 145 to 42 × 10⁹/L over a short interval deserves attention even before the familiar textbook pattern is complete.
An LDH of 900 IU/L may support hemolysis or organ injury, but it cannot identify TTP on its own because LDH comes from several tissues. The LDH result interpretation guide explains that limitation; clinicians pair LDH with bilirubin fractions, reticulocytes, the smear, and other evidence rather than treating one elevated enzyme as a diagnosis.
Haptoglobin below a laboratory's detection limit supports intravascular hemolysis, although liver disease can also lower it and an inflammatory response can partially mask the expected reduction. The low haptoglobin guide covers those exceptions; an activity of 6% becomes much more persuasive when several independent markers point toward the same microvascular process.
When should you seek emergency assessment?
Suspected TTP is a medical emergency, and clinicians should not wait for ADAMTS13 results before initiating the appropriate urgent pathway. New confusion, weakness, seizures, chest pain, breathlessness, or severe illness alongside low platelets or suspected hemolysis requires immediate emergency assessment.
A new activity result below 10% in someone being investigated for thrombocytopenia or hemolysis needs immediate contact with the treating team, even if symptoms seem modest. If that team cannot be reached promptly, emergency assessment is safer than waiting for a routine appointment; someone already under a documented remission-monitoring plan should follow that team's specific instructions.
Chest discomfort in suspected TTP may reflect cardiac microvascular injury, and it can occur without the usual coronary risk profile. Our chest pain laboratory guide explains why troponin and ECG assessment belong in urgent care, but neither a reassuring initial ECG nor an activity result above 10% after plasma treatment should independently end the evaluation.
Emergency teams usually collect a CBC, smear, hemolysis markers, kidney tests, coagulation studies, and a pretreatment ADAMTS13 sample while arranging hematology input. The practical rule is simple: if obtaining that sample would delay lifesaving treatment, treatment comes first; a send-out test that takes 24 hours or several days cannot serve as permission to wait.
How do activity, inhibitor, and antibody tests differ?
ADAMTS13 activity measures enzyme function, inhibitor testing measures functional neutralization, and antibody testing detects immune binding to ADAMTS13. These are related but different questions; activity of 5%, a negative inhibitor assay, and a positive antibody result can be a biologically coherent combination.
En activity assay asks how efficiently the sample cleaves a defined substrate under laboratory conditions, usually reporting the result as a percentage of a reference preparation. An activity of 7% therefore means markedly impaired measured function; it does not reveal whether the cause is an autoantibody, an inherited deficiency, or another explanation without additional investigation.
A functional inhibitor assay typically mixes patient plasma with a source of normal ADAMTS13 and checks for loss of activity after incubation. Laboratories may report inhibitor titers in Bethesda units per milliliter, but a result such as 1 BU/mL must be interpreted using that laboratory's method and positivity threshold; there is no universal antibody-to-inhibitor conversion.
En anti-ADAMTS13 antibody assay, commonly an IgG binding assay, can detect antibodies that accelerate enzyme clearance without strongly neutralizing the substrate reaction in vitro. Our positiv antistoffresultatguide explains this broader distinction; a negative inhibitor result does not rule out immune TTP when activity is below 10% and other evidence supports it.
Can plasma treatment change an ADAMTS13 test?
Plasma infusion and plasma exchange can raise measured ADAMTS13 activity because donor plasma supplies the enzyme. Exchange can also remove or dilute inhibitors and antibodies, so a result obtained after treatment may underestimate the severity of the original deficiency or obscure its immune cause.
Whenever feasible, clinicians collect the ADAMTS13 sample before the first plasma infusion or exchange, ideally before other relevant treatment begins. The 2020 ISTH diagnostic guideline explicitly emphasizes pretreatment sampling (Zheng et al., 2020); the instruction is not to postpone care, but to obtain a useful sample while the urgent treatment pathway is already being organized.
For example, a pretreatment activity of 2% and a post-exchange activity of 18% can describe the same patient rather than two contradictory diagnoses. The later value reflects the mixture of disease biology and treatment effect; ask the hospital laboratory whether an earlier retained plasma aliquot exists before assuming that the initial diagnostic opportunity has been lost.
There is no safe universal instruction to stop plasma therapy and wait a fixed number of days simply to produce a cleaner result. The post-transfusion A1c guide illustrates a different treatment-related testing problem, but the mechanisms are not interchangeable: for ADAMTS13, record the collection time and all preceding plasma or enzyme-replacement treatment, including even 1 prior infusion.
Could the assay method or sample quality mislead you?
ADAMTS13 results can be affected by assay design, specimen handling, and method-specific interference. A surprising result near 10% deserves discussion with the laboratory, especially if the sample was collected after treatment or the measured activity does not fit the rest of the clinical picture.
Common methods measure cleavage of a von Willebrand factor-derived substrate; some use fluorescence, while others detect cleavage products through different readouts. Bilirubin, hemoglobin, or other sample constituents can interfere with particular systems, but the direction and magnitude are method-dependent; do not assume that every visibly altered sample produces a falsely low ADAMTS13 activity of 8%.
Testing laboratories commonly request citrert plasma, with processing, freezing, and transport instructions specific to the assay. Our high hemolysis index guide explains why collection-related sample damage differs from hemolysis occurring inside the patient; that distinction matters because TTP itself can produce hemolysis even when the laboratory specimen has been collected correctly.
Kantesti er en AI-blodprøvetolkningsplattform that can help readers identify the reported percentage, reference interval, and collection date, but it cannot inspect an assay's raw signal or validate an unexpected 9% result. My practical question is whether the laboratory recommends confirmation on a retained pretreatment sample or another assay—not whether the patient should wait untreated for perfect certainty.
What else can cause reduced ADAMTS13 activity?
Sepsis, advanced liver disease, and several systemic illnesses can cause reduced ADAMTS13 activity without classic TTP. Reductions above 20% are generally less specific, while results of 10–20% form an interpretive gray zone; severe deficiency still demands careful specialist evaluation rather than automatic attribution to another illness.
En verdi på 35% in a critically ill patient with sepsis and abnormal coagulation tests is not equivalent to 3% in someone with otherwise unexplained thrombocytopenia and hemolysis. Clinical reasoning also considers disseminated intravascular coagulation, medication-associated microangiopathy, severe hypertension, and complement-mediated disease; occasionally overlapping conditions make the initial classification genuinely difficult.
Pregnancy and the postpartum period require particular care because TTP, HELLP syndrome, and complement-mediated microangiopathy can share several findings. The HELLP nødlaboratorieveiledning describes the obstetric pattern, but activity below 10% should not be dismissed as a normal pregnancy-related change; maternal and hematology teams often need to evaluate the situation together.
Marked kidney dysfunction may shift attention toward another microangiopathy, but it does not exclude TTP, particularly when pretreatment activity is severely deficient. Our urgent low eGFR guide discusses kidney warning signs; a creatinine of 3 mg/dL is a clue about organ involvement, not a stand-alone rule for deciding which microangiopathy is present.
How does the PLASMIC score help before results return?
The PLASMIC score estimates the likelihood of severe ADAMTS13 deficiency in adults with suspected thrombotic microangiopathy. Scores of 6–7 indicate high probability, 5 is intermediate, and 0–4 is low probability; the score supports urgent reasoning but does not diagnose TTP or replace clinical judgment.
The score assigns 1 point each for platelets below 30 × 10⁹/L, evidence of hemolysis, no active cancer, no transplant history, MCV below 90 fL, INR below 1.5, and creatinine below 2 mg/dL. Bendapudi and colleagues developed and externally validated this approach in adults with thrombotic microangiopathies, rather than in people with an isolated mildly low platelet count (Bendapudi et al., 2017).
Its hemolysis component can be met by a reticulocyte count above 2.5%, undetectable haptoglobin, or indirect bilirubin above 2 mg/dL. A relatively normal INR fits the TTP pattern because routine coagulation tests do not measure the same process; the normal coagulation test limitations guide explains why reassuring clotting times cannot exclude microvascular platelet aggregation.
Scores become less dependable when applied outside their validated context, including children and some pregnancy, cancer, transplant, or complex critical-care presentations. A score of 4 must not overrule a compelling specialist assessment, just as a score of 7 is not proof; clinicians use the estimate to inform immediate action while obtaining the actual pretreatment activity result.
Does severe deficiency mean immune or congenital TTP?
Severe ADAMTS13 deficiency can result from immune TTP or congenital TTP. Immune disease involves autoantibodies; congenital disease usually involves pathogenic variants in both copies of the ADAMTS13 gene, and a negative inhibitor assay alone cannot reliably distinguish these two mechanisms.
A person with activity of 1% and convincing anti-ADAMTS13 antibodies usually has evidence favoring immune TTP, although the full report and timing still matter. Conversely, negative antibodies obtained after plasma exchange or immunosuppression are weaker evidence against an immune mechanism; clinicians may review pretreatment testing and repeat selected investigations once interpretation is less confounded.
Congenital TTP can present in childhood, but some people first become symptomatic during pregnancy or another physiological stress in adulthood. Persistent activity below 10%, repeatedly negative immune studies, and a compatible history may prompt genetic testing; a family history can help, but its absence does not exclude an autosomal recessive condition in which both parents are unaffected carriers.
Finding 1 ADAMTS13 variant does not automatically establish congenital TTP, because variant classification and the second gene copy matter. Kantesti's veiledning for blodprøvemarkører helps distinguish functional laboratory measurements from genetic findings; treatment choice ultimately depends on establishing the mechanism, not simply renaming every antibody-negative low result as inherited disease.
How do ADAMTS13 results influence urgent treatment?
Suspected immune TTP is generally treated urgently with plasma exchange and corticosteroids, with specialist decisions about caplacizumab and immune-directed therapy. Confirmed congenital TTP instead requires ADAMTS13 replacement; activity below 10% helps establish the mechanism but is not a reason to postpone initial lifesaving care.
Plasma exchange addresses 2 problems in immune TTP: it provides functional enzyme and removes circulating pathogenic factors, while corticosteroids and often rituximab target the immune process. Caplacizumab blocks the von Willebrand factor–platelet interaction rather than correcting enzyme deficiency, so a rising platelet count during treatment does not necessarily mean ADAMTS13 activity has recovered.
In the HERCULES trial, the composite of TTP-related death, recurrence, or major thromboembolic events during treatment occurred in 12% of caplacizumab recipients versus 49% of placebo recipients, alongside standard care (Scully et al., 2019). Those figures describe a trial outcome, not an individual's prognosis; caplacizumab also increases bleeding risk, so prescribing and duration require specialist oversight.
Congenital TTP may be treated with plasma-based replacement or recombinant ADAMTS13 where available and appropriate; immunosuppression does not repair an inherited enzyme defect. Our veiledning for koagulasjonstesting explains why routine clotting times cannot measure this replacement response; platelet transfusion is generally avoided in TTP unless a compelling indication, such as life-threatening bleeding, changes the balance.
What does low activity mean after TTP treatment?
Low ADAMTS13 activity during remission indicates ongoing deficiency and increased relapse risk, but it does not automatically mean an acute clinical relapse. A person can have activity below 10% with a normal platelet count and no active hemolysis; that still needs prompt hematology follow-up.
Clinical recovery is assessed through platelet recovery, resolution of hemolysis, and organ status, not activity alone. For example, platelets of 210 × 10⁹/L with stable hemoglobin and activity of 7% differ from platelets of 24 × 10⁹/L with renewed hemolysis; neither result should be interpreted without knowing whether this is initial diagnosis, treatment response, or remission surveillance.
Some follow-up frameworks describe an ADAMTS13 relapse as a fall below 20% after prior enzyme recovery, even without an acute clinical episode. That biochemical warning can lead to closer monitoring or preemptive immune-directed treatment in selected patients; our post-hospital laboratory changes guide explains why the treatment timeline belongs beside each result.
Monitoring may occur every 1–3 months in parts of follow-up, with different intervals according to recovery, previous relapses, pregnancy plans, and local practice. Kantesti can help organize reported trends through the medication safety trend workflow, but new neurological symptoms, chest pain, or falling platelets require direct clinical assessment rather than waiting for the next scheduled upload.
How can Kantesti help without delaying emergency care?
Kantesti can help explain an ADAMTS13 report, but it cannot diagnose or exclude acute TTP remotely. The useful workflow is to review the percentage, accompanying CBC and hemolysis results, and treatment timing after arranging urgent care when the presentation suggests TTP—not before.
Kantesti er en Analyseverktøy for blodprøver drevet av KI that supports patient understanding of laboratory terminology, including the difference between activity below 10% and a positive inhibitor result. As an organization, we explain our scope on the Om oss-side; reader understanding is the goal, not an automated declaration that a potentially dangerous result is harmless.
The safest report review checks 4 items before discussing a trend: patient identity, collection date, units or percentage, and treatment received before collection. Our technical and clinical standards describe the evaluation framework, but no benchmark can substitute for checking the original laboratory document or knowing whether a sample followed plasma exchange.
A PDF or photo can omit an inhibitor comment, a specimen warning, or the fact that activity was measured after 2 exchanges; those omissions can change the interpretation substantially. The veiledning for AI-teknologi explains the report-processing approach, while my editorial priority as Thomas Klein, MD, remains straightforward: an explanation must never become a reason to delay emergency hematology care.
Research publications, evidence limits, and source checks
TTP decisions should be grounded in specialist guidelines and directly relevant clinical studies, not unrelated laboratory education publications. As of October 8, 2026, this article uses the verified 2020 ISTH diagnostic guideline, the 2017 PLASMIC study, and the 2019 HERCULES trial for its principal clinical claims.
Det 3 external medical references listed below address different questions: diagnosis and pretreatment sampling, estimating severe deficiency before results return, and caplacizumab outcomes during treatment. Their publication dates are stated explicitly; the date of this article does not imply that a new 2026 guideline exists, and local hematology protocols may incorporate additional evidence or country-specific access arrangements.
Det 2 Figshare DOI resources listed separately are broader educational materials, not evidence validating an ADAMTS13 cutoff or TTP treatment. Their associated articles cover digestive symptom interpretation og hormonal health questions; a DOI identifies a deposited resource but does not by itself demonstrate peer review, clinical relevance, or independent validation.
ResearchGate and Academia.edu links below are explicitly 2 discovery searches, not verified copies or endorsements of those deposits; publication dates are shown as unknown rather than invented. Kantesti's medisinske rådgivende styre provides information about physician expertise, but that organizational page should not be interpreted as documentation that any named physician personally reviewed this individual article.
Ofte stilte spørsmål
Betyr ADAMTS13-aktivitet under 10 prosent at jeg definitivt har TTP?
ADAMTS13-aktivitet under 10% støtter sterkt TTP når trombocytopeni og mikroangiopatisk hemolytisk anemi opptrer sammen. Den beviser ikke automatisk en akutt episode fordi alvorlig mangel kan vedvare under remisjon eller forekomme ved medfødt TTP uten nåværende symptomer. Tidspunktet for prøvetaking, tidligere behandling, resultater fra undersøkelse for hemmere og antistoffer, og kliniske funn har alle betydning. En ny mistenkt TTP-presentasjon krever akutt vurdering uten å vente på bekreftelse.
Kan man ha TTP med ADAMTS13-aktivitet over 10%?
Et ADAMTS13 aktivitetsresultat over 10% utelukker ikke TTP på en sikker måte hvis prøven ble tatt etter plasma-infusjon eller -utveksling. Pre-behandlingsresultater på 10–20% er en fortolkningsmessig gråsone som kan kreve gjentatt eller alternativ-metode testing. Et pålitelig pre-behandlingsresultat over 20% flytter generelt evalueringen mot andre årsaker til trombotisk mikroangiopati. Sterk klinisk mistanke krever fortsatt øyeblikkelig spesialistvurdering mens uoverensstemmelser undersøkes.
Hva er forskjellen mellom en ADAMTS13-hemmer og et antistoff?
En ADAMTS13-hemmeranalyse påviser funksjonell nøytralisering av enzymet, mens en antistoffanalyse påviser immunbinding til ADAMTS13. Aktivitet rapporteres separat, vanligvis som en prosentandel, og et resultat på 5% indikerer sterkt nedsatt målt enzymfunksjon. Noen antistoffer fremmer enzymklaring uten å produsere en positiv funksjonell hemmeranalyse. Derfor utelukker et negativt hemmerresultat i seg selv ikke immun TTP.
Bør ADAMTS13-testen gjøres før plasmautveksling?
ADAMTS13-testen bør ideelt sett tas før den første plasma-infusjonen eller plasmautskiftningen fordi donorens plasma inneholder funksjonelt enzym. Utskiftning kan også fjerne eller fortynne inhibitorer og antistoffer, noe som gjør et senere resultat mindre representativt for den opprinnelige sykdommen. En aktivitet etter behandling på 18% kan følge en aktivitet før behandling under 10%. Prøvetaking må ikke forsinke akuttbehandling når TTP sterkt mistenkes.
Er ADAMTS13-aktivitet på 30% en nødsituasjon?
ADAMTS13-aktivitet på 30% er redusert i mange laboratorier, men er ikke den alvorlige mangelen under 10% som sterkt støtter TTP. Tallet alene bestemmer ikke om det foreligger en nødsituasjon. Lave blodplater, aktiv hemolyse, forvirring, brystsmerter eller annen organskade berettiger fortsatt til akutt vurdering, inkludert undersøkelse for andre mikroangiopatier. En stabil person uten disse funnene trenger tolkning ved hjelp av laboratorieintervaller og klinisk historie heller enn automatisk merking som nødsituasjon.
Can ADAMTS13 stay low even when my platelets are normal?
ADAMTS13 activity can remain below 10% during TTP remission even when platelets are normal and hemolysis has resolved. This pattern indicates persistent enzyme deficiency and can signal increased relapse risk, rather than automatically proving a current acute relapse. Some monitoring frameworks use activity below 20% after previous recovery as a biochemical relapse warning. A hematologist should decide whether closer surveillance or preemptive treatment is appropriate.
How long do ADAMTS13 results take, and can treatment wait?
ADAMTS13 turnaround varies by hospital and assay, ranging from rapid local testing to send-out results that take several days. A result expected in 24–72 hours is not a reason to postpone treatment when TTP is strongly suspected. Emergency teams use the clinical presentation, routine laboratory findings, and sometimes the PLASMIC score while arranging specialist care. The preferred sequence is prompt pretreatment sampling when feasible, followed by urgent treatment decisions without waiting for the result.
Få AI-drevet analyse av blodprøver i dag
Bli med over 2 millioner brukere over hele verden som stoler på Kantesti for øyeblikkelig, nøyaktig analyse av laboratorietester. Last opp blodprøveresultatene dine og få omfattende tolkning av 15,000+-biomarkører på sekunder.
📚 Refererte forskningspublikasjoner
Klein, T., Mitchell, S., & Weber, H. (2026). Diaré etter faste, svarte prikker i avføringen og GI-veiledning 2026. Kantesti KI medisinsk forskning.
Klein, T., Mitchell, S., & Weber, H. (2026). Women's Health Guide: Ovulation, Menopause & Hormonal Symptoms. Kantesti KI medisinsk forskning.
📖 Eksterne medisinske referanser
Zheng XL et al. (2020). ISTH-retningslinjer for diagnostisering av trombotisk trombocytopenisk purpura. Journal of Thrombosis and Haemostasis.
Bendapudi PK et al. (2017). Derivation and external validation of the PLASMIC score for rapid assessment of adults with thrombotic microangiopathies: a cohort study. The Lancet Haematology.
Scully M et al. (2019). Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura. New England Journal of Medicine.
⚕️ Medisinsk ansvarsfraskrivelse
Denne artikkelen er kun for informasjonsformål og utgjør ikke medisinsk rådgivning. Rådfør deg alltid med en kvalifisert helsepersonell for beslutninger om diagnose og behandling.
E-E-A-T tillitssignaler
Experience
Klinisk gjennomgang ledet av lege av arbeidsflyter for laboratorietolkning.
Expertise
Fagområde laboratoriemedisin med fokus på hvordan biomarkører oppfører seg i klinisk kontekst.
Authoritativeness
Skrevet av Dr. Thomas Klein med gjennomgang av Dr. Sarah Mitchell og Prof. Dr. Hans Weber.
Trustworthiness
Evidensbasert tolkning med tydelige oppfølgingsveier for å redusere uro.